Tempus AI, Inc. (TEM)
Market Cap | 12.46B |
Revenue (ttm) | 803.32M |
Net Income (ttm) | -721.31M |
Shares Out | 173.12M |
EPS (ttm) | -4.92 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 10,201,946 |
Open | 72.15 |
Previous Close | 71.28 |
Day's Range | 71.22 - 74.83 |
52-Week Range | 22.89 - 91.45 |
Beta | n/a |
Analysts | Buy |
Price Target | 63.90 (-11.25%) |
Earnings Date | Aug 5, 2025 |
About TEM
Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharma... [Read more]
Financial Performance
In 2024, Tempus AI's revenue was $693.40 million, an increase of 30.38% compared to the previous year's $531.82 million. Losses were -$746.33 million, 180.6% more than in 2023.
Financial numbers in USD Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for TEM stock is "Buy." The 12-month stock price forecast is $63.9, which is a decrease of -11.25% from the latest price.
News

Shamis & Gentile, P.A. Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Tempus AI, Inc. and Sets a Lead Plaintiff Deadline of August 12, 2025
MIAMI, June 13, 2025 (GLOBE NEWSWIRE) -- The following statement is being issued by Shamis & Gentile, P.A: To: All persons or entities who purchased or otherwise acquired Tempus AI, Inc. (“Tempus” or ...

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Tempus AI, Inc. (TEM) and Encourages Shareholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / June 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tempus AI, Inc. ("Tempus" or "the Company") (NASDA...

Tempus Announces Collaboration with Northwestern University's Abrams Research Center on Neurogenomics to Leverage AI for Alzheimer's Disease Research
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with The Abrams...

Tempus AI, Inc. (TEM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / June 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tempus AI, Inc. ("Tempus" or "the Company") (NASDA...

Bronstein, Gewirtz & Grossman, LLC Encourages Tempus AI, Inc. (TEM) Shareholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / June 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tempus AI, Inc. ("Tempus" or "the Company") (NASDA...

Bronstein, Gewirtz & Grossman, LLC Is Investigating Tempus AI, Inc. (TEM) And Encourages Shareholders to Connect
NEW YORK CITY, NY / ACCESS Newswire / June 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ...

Bronstein, Gewirtz & Grossman, LLC Encourages Tempus AI, Inc. (TEM) Stockholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / June 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ...

I'm Still Bullish On Tempus AI
TEM is a data-rich platform that recently clinched a $200 million deal with AstraZeneca. TEM's main bet is now on AI for healthcare applications. I believe TEM's main business moat is its vast and rap...

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Tempus AI, Inc. (TEM) and Encourages Investors to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / June 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ...

Tempus AI, Inc. (TEM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ...

Bronstein, Gewirtz & Grossman, LLC Is Investigating Tempus AI, Inc. (TEM) And Encourages Investors to Connect
NEW YORK CITY, NY / ACCESS Newswire / June 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ...

Tempus AI, Inc. (TEM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / June 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ...

Tempus Introduces xM, An Assay to Monitor Immunotherapy Response for Patients with Advanced Cancers
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced xM for treatment response monit...

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Tempus AI, Inc. (TEM) and Encourages Stockholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / June 1, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ...

Introducing Tempus One in the EHR with Integrated Guidelines
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the expansion of Tempus One—its...

Tempus Introduces Fuses, A Program Designed to Transform Therapeutic Research and Build the Largest Diagnostic Platform Using its Novel Foundation Model
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the launch of its Fuses program...

Bronstein, Gewirtz & Grossman, LLC Encourages Tempus AI, Inc. (TEM) Investors to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / May 30, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ...

Tempus Announces 10 Abstracts Accepted for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that ten abstracts have been ac...

Tempus AI, Inc. Investors: Company Investigated by the Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses

Tempus Fugit, Investors Regret? Short Seller Targets AI Darling, Warns CEO Is 'Cash Out King' (UPDATED)
Editor's note: This story has been updated to include a statement from a Tempus AI spokesperson.

Tempus: Short Seller Attack Brings Golden Opportunity Cathie Wood Was Waiting For
Tempus AI Inc. TEM just got hit with a short seller grenade—and Cathie Wood showed up with a shopping cart.

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Tempus AI, Inc. (TEM) And Encourages Investors to Reach Out
NEW YORK CITY, NY / ACCESS Newswire / May 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ...

Tempus AI, Inc. (NASDAQ: TEM) Securities Fraud Investigation; Investors Urged to Contact Award-Winning Firm, Gibbs Mura
OAKLAND, Calif.--(BUSINESS WIRE)---- $TEM #TEM--Gibbs Mura, A Law Group, is investigating potential legal claims on behalf of shareholders with losses in Tempus AI, Inc. (NASDAQ: TEM).

TEM Investors Have Opportunity to Join Tempus AI, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)--TEM Investors Have Opportunity to Join Tempus AI, Inc. Fraud Investigation with the Schall Law Firm.

Tempus AI stock wasn't worth owning even without the short report: find out why
Tempus AI Inc (NASDAQ: TEM) came crumbling down on Wednesday after Spruce Point announced a short position in the Chicago headquartered health technology company. Spruce Point cited several reasons, i...